Cargando…

Macrovascular complication phenotypes in type 2 diabetic patients

BACKGROUND: Macrovascular diseases (MVD) in type 2 diabetes mellitus (T2DM) are often considered all together, without discriminating the areas involved. The aim of our study was to analyse MVD prevalence in a large population of T2DM patients by dividing the cases into subgroups according to MVD si...

Descripción completa

Detalles Bibliográficos
Autores principales: Papa, Giuseppe, Degano, Claudia, Iurato, Maria P, Licciardello, Carmelo, Maiorana, Raffaella, Finocchiaro, Concetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558439/
https://www.ncbi.nlm.nih.gov/pubmed/23331854
http://dx.doi.org/10.1186/1475-2840-12-20
_version_ 1782257436615245824
author Papa, Giuseppe
Degano, Claudia
Iurato, Maria P
Licciardello, Carmelo
Maiorana, Raffaella
Finocchiaro, Concetta
author_facet Papa, Giuseppe
Degano, Claudia
Iurato, Maria P
Licciardello, Carmelo
Maiorana, Raffaella
Finocchiaro, Concetta
author_sort Papa, Giuseppe
collection PubMed
description BACKGROUND: Macrovascular diseases (MVD) in type 2 diabetes mellitus (T2DM) are often considered all together, without discriminating the areas involved. The aim of our study was to analyse MVD prevalence in a large population of T2DM patients by dividing the cases into subgroups according to MVD sites (NMVD, no MVD; NSCS, non-significant carotid stenosis; CBVD, cerebrovascular disease; CAD, coronary artery disease; PAD, peripheral artery disease; PVD, polyvascular disease) and studying the anthropometric, clinical and laboratory parameters in each group. METHODS: A diabetic outpatient cohort (n = 1199) was retrospectively studied. Demographic, clinical and laboratory parameters were included in analyses. A thorough cardiovascular history as documented by previous medical records (including medical and hospital records) and vascular laboratory studies (including standardised electrocardiogram, echocardiogram, provocative tests for cardiac ischaemia, ankle/brachial index, duplex ultrasonography of the carotid and lower limbs and, in selected cases, computed tomography angiography, carotid and peripheral arteriography and evaluation of transcutaneous oxygen pressure), was collected for all of the patients. Standardised procedures were used to assess microvascular complications as well as metabolic syndrome (Mets). RESULTS: The unadjusted MVD prevalence was 46.4% among the participants. The majority of patients with MVD were in the PVD group. In the multivariate analysis, age, male sex and diabetes duration were independent risk factors for PAD and PVD (P < 0.01). A low HDL-C value was an independent risk factor in the CAD and PVD groups (P = 0.03). Very high frequencies of MetS were observed in the PAD and PVD groups (94.9 and 95.7% respectively). The most MetS diagnostic criteria were recorded among members of the CAD group (all or all-1 criteria were present in 73% of patients). The average age in the CAD group (64.5 y) was comparable to that of the NMVD group. Microvascular complications were more frequent in the PAD and PVD patients. CONCLUSION: Phenotypic heterogeneity is associated with different macrovascular complications in T2DM patients. These findings might have clinical implications for developing diagnostic and therapeutic strategies targeting type 2 diabetes.
format Online
Article
Text
id pubmed-3558439
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35584392013-01-31 Macrovascular complication phenotypes in type 2 diabetic patients Papa, Giuseppe Degano, Claudia Iurato, Maria P Licciardello, Carmelo Maiorana, Raffaella Finocchiaro, Concetta Cardiovasc Diabetol Original Investigation BACKGROUND: Macrovascular diseases (MVD) in type 2 diabetes mellitus (T2DM) are often considered all together, without discriminating the areas involved. The aim of our study was to analyse MVD prevalence in a large population of T2DM patients by dividing the cases into subgroups according to MVD sites (NMVD, no MVD; NSCS, non-significant carotid stenosis; CBVD, cerebrovascular disease; CAD, coronary artery disease; PAD, peripheral artery disease; PVD, polyvascular disease) and studying the anthropometric, clinical and laboratory parameters in each group. METHODS: A diabetic outpatient cohort (n = 1199) was retrospectively studied. Demographic, clinical and laboratory parameters were included in analyses. A thorough cardiovascular history as documented by previous medical records (including medical and hospital records) and vascular laboratory studies (including standardised electrocardiogram, echocardiogram, provocative tests for cardiac ischaemia, ankle/brachial index, duplex ultrasonography of the carotid and lower limbs and, in selected cases, computed tomography angiography, carotid and peripheral arteriography and evaluation of transcutaneous oxygen pressure), was collected for all of the patients. Standardised procedures were used to assess microvascular complications as well as metabolic syndrome (Mets). RESULTS: The unadjusted MVD prevalence was 46.4% among the participants. The majority of patients with MVD were in the PVD group. In the multivariate analysis, age, male sex and diabetes duration were independent risk factors for PAD and PVD (P < 0.01). A low HDL-C value was an independent risk factor in the CAD and PVD groups (P = 0.03). Very high frequencies of MetS were observed in the PAD and PVD groups (94.9 and 95.7% respectively). The most MetS diagnostic criteria were recorded among members of the CAD group (all or all-1 criteria were present in 73% of patients). The average age in the CAD group (64.5 y) was comparable to that of the NMVD group. Microvascular complications were more frequent in the PAD and PVD patients. CONCLUSION: Phenotypic heterogeneity is associated with different macrovascular complications in T2DM patients. These findings might have clinical implications for developing diagnostic and therapeutic strategies targeting type 2 diabetes. BioMed Central 2013-01-18 /pmc/articles/PMC3558439/ /pubmed/23331854 http://dx.doi.org/10.1186/1475-2840-12-20 Text en Copyright ©2013 Papa et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Investigation
Papa, Giuseppe
Degano, Claudia
Iurato, Maria P
Licciardello, Carmelo
Maiorana, Raffaella
Finocchiaro, Concetta
Macrovascular complication phenotypes in type 2 diabetic patients
title Macrovascular complication phenotypes in type 2 diabetic patients
title_full Macrovascular complication phenotypes in type 2 diabetic patients
title_fullStr Macrovascular complication phenotypes in type 2 diabetic patients
title_full_unstemmed Macrovascular complication phenotypes in type 2 diabetic patients
title_short Macrovascular complication phenotypes in type 2 diabetic patients
title_sort macrovascular complication phenotypes in type 2 diabetic patients
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558439/
https://www.ncbi.nlm.nih.gov/pubmed/23331854
http://dx.doi.org/10.1186/1475-2840-12-20
work_keys_str_mv AT papagiuseppe macrovascularcomplicationphenotypesintype2diabeticpatients
AT deganoclaudia macrovascularcomplicationphenotypesintype2diabeticpatients
AT iuratomariap macrovascularcomplicationphenotypesintype2diabeticpatients
AT licciardellocarmelo macrovascularcomplicationphenotypesintype2diabeticpatients
AT maioranaraffaella macrovascularcomplicationphenotypesintype2diabeticpatients
AT finocchiaroconcetta macrovascularcomplicationphenotypesintype2diabeticpatients